Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in...

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Cisplatin resistance significantly challenges ovarian cancer treatment.
• dCTP pyrophosphatase 1 (DCTPP1) is a newly identified enzyme influencing cancer traits and drug responses.

Purpose of the Study:

• To investigate the role of DCTPP1 in ovarian cancer progression.
• To determine DCTPP1's impact on cisplatin response and resistance.

Main Methods:

• Bioinformatic analysis of publicly available ovarian cancer databases.
• Analysis of DCTPP1 expression in cisplatin-sensitive and resistant cell lines (SKOV3/S, SKOV3/DDP) and patient samples.
• Investigation of DCTPP1's effect on reactive oxygen species (ROS) and oxidative stress.

Main Results:

• DCTPP1 is significantly overexpressed in ovarian cancer, correlating with tumor progression and poor prognosis post-cisplatin treatment.
• DCTPP1 is linked to cisplatin resistance pathways, including pyrimidine metabolism and P53 signaling.
• Higher DCTPP1 expression observed in resistant cells/samples; its knockout reversed cisplatin resistance by increasing ROS and antioxidant response.

Conclusions:

• DCTPP1 is a potential prognostic biomarker for ovarian cancer patients.
• Targeting DCTPP1 presents a promising strategy to overcome cisplatin resistance in ovarian cancer therapy.